about
Cancer stem cells and signaling pathways in radioresistanceCombination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells.Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance.Monitoring Prostate Tumor Growth in an Orthotopic Mouse Model Using Three-Dimensional Ultrasound Imaging Technique.Identification of protein biomarkers and signaling pathways associated with prostate cancer radioresistance using label-free LC-MS/MS proteomic approach.Proteomic identification of the lactate dehydrogenase A in a radioresistant prostate cancer xenograft mouse model for improving radiotherapy.Role of the EpCAM (CD326) in prostate cancer metastasis and progression.The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.Cancer stem cells in prostate cancer chemoresistance.Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.Proteomics discovery of chemoresistant biomarkers for ovarian cancer therapy.PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways.Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance.Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.Urinary biomarkers in prostate cancer detection and monitoring progression.
P50
Q26771576-14509F6B-0297-480B-B949-E374D9DC9256Q31133958-A3840058-F1BA-4B99-9ABF-DDCDDF8EAD68Q35001678-EDE97AD9-4924-496C-A8F3-ED1531E27977Q35116847-61C4B239-2B3C-4610-B76D-5A7BD35FBBE7Q36707148-2C7E662F-A303-4ED2-BD47-5AAF959D8A2AQ37657753-A97BF10C-516F-4FB1-ADE1-A14FB37FF5F6Q37687556-A405EEF4-F12B-4C07-A157-21A187C97E98Q38020426-AAD661E1-1814-44ED-B875-4FD33A9D7903Q38100999-78C5A5E4-12D2-4E72-A7E1-9F77D2258D59Q38203548-A2C3EDB8-FB45-4C75-BD83-3C499594E53DQ38562615-B10E14A4-2880-4469-BA44-EE9F538A11AEQ38824059-98530125-9481-4F51-A6A6-B0E15F561EF5Q38951260-62890D1F-23D8-4D8F-9121-70BE9F9DCCCBQ39070920-56DF8049-CE5C-4166-B9DD-B4EB42557565Q39275045-7191CA77-C73C-4525-8DDC-31AE9027B4FDQ42317503-6DA762E8-6E7D-412B-80CB-8E67F9D0B036Q47792567-DAC892BB-C5C2-4E08-9567-0DCC5EC769E6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jie Ni
@ast
Jie Ni
@en
Jie Ni
@es
Jie Ni
@nl
Jie Ni
@sl
type
label
Jie Ni
@ast
Jie Ni
@en
Jie Ni
@es
Jie Ni
@nl
Jie Ni
@sl
altLabel
Kevin Ni
@en
prefLabel
Jie Ni
@ast
Jie Ni
@en
Jie Ni
@es
Jie Ni
@nl
Jie Ni
@sl
P106
P1153
55252550600
P31
P496
0000-0002-8844-6132